| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 75736 |
MAL-di-EG-Val-Cit-PAB-MMAF， ADC试剂 |
85 |
kx |
2024-12-19 |
| 75737 |
cas:2353409-45-5 endo BCN-PEG3-VC-PFP Ester |
98 |
zyl |
2024-12-19 |
| 75738 |
Hydrazone-doxorubicin， ADC试剂 |
169 |
kx |
2024-12-19 |
| 75739 |
DBCO-C4-Val-Cit-PABC-PNP |
77 |
zyl |
2024-12-19 |
| 75740 |
cas:644981-35-1 Val-Cit-PAB-MMAE |
84 |
zyl |
2024-12-19 |
| 75741 |
cas:170908-81-3，DOTA-NHS ester ，1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸 1-(2,5-二氧代-1-吡咯烷基)酯 |
73 |
kx |
2024-12-19 |
| 75742 |
endo-BCN-PEG4-Val-Cit-PAB-MMAE的介绍 |
82 |
zyl |
2024-12-19 |
| 75743 |
cas:2259318-50-6，MA-PEG4-VA-PBD ， ADC试剂 |
97 |
kx |
2024-12-19 |
| 75744 |
CAS: 2259318-55-1 - DBCO-(PEG2-VC-PAB-MMAE)2 |
65 |
WYQ |
2024-12-19 |
| 75745 |
CAS: 2768446-73-5，DBCO-Val-Cit-PAB-MMAE |
79 |
WYQ |
2024-12-19 |
| 75746 |
MC-vc-PAB-C6-a-amanitin， ADC试剂 |
70 |
kx |
2024-12-19 |
| 75747 |
cas:663598-98-9，2,5-dioxopyrrolidin-1-yl 4-methyl-4-((5-nitropyridin-2-yl)disulfanyl)pentanoate，ADC定制 |
90 |
wyh |
2024-12-19 |
| 75748 |
cas:2873452-49-2 MC-EVCit-PAB-MMAE |
87 |
zyl |
2024-12-19 |
| 75749 |
2,5-dioxopyrrolidin-1-yl 3-methyl-3-(pyridin-2-yldisulfanyl)butanoate，ADC定制 |
95 |
wyh |
2024-12-19 |
| 75750 |
cas:159857-70-2 MC-Val-Cit-Doxorubicin |
118 |
zyl |
2024-12-19 |
| 75751 |
Gly3-vc-PAB-MMAE， ADC试剂 |
103 |
kx |
2024-12-19 |
| 75752 |
CAS: 1869126-64-6， Azido-PEG4-Val-Cit-PAB-MMAE |
87 |
WYQ |
2024-12-19 |
| 75753 |
cas:2353409-54-6 ， Mal-amido-PEG8-Val-Gly，ADC定制 |
104 |
wyh |
2024-12-19 |
| 75754 |
Azido-PEG4-Val-Ala-PAB-PNP |
99 |
zyl |
2024-12-19 |
| 75755 |
NOTA-(NGR)2 NOTA偶联NGR二聚体 |
78 |
h |
2024-12-19 |
| 75756 |
1-(2,5-dioxopyrrolidin-1-yloxy)-4-((5-nitropyridin-2-yl)disulfanyl)-1-oxobutane-2-sulfonic acid，ADC定制 |
89 |
wyh |
2024-12-19 |
| 75757 |
CAS: 1343476-44-7，Val-Ala-PAB-OH |
79 |
WYQ |
2024-12-19 |
| 75758 |
MC-PBD， ADC试剂 |
88 |
kx |
2024-12-19 |
| 75759 |
Mal-Val-Ala-PAB的介绍 |
90 |
zyl |
2024-12-19 |
| 75760 |
DOTA-K-A9 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)结合肽A9 |
79 |
h |
2024-12-19 |
| 75761 |
Azide-PEG3-Val-Cit-PAB-MMAF，叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
83 |
WYQ |
2024-12-19 |
| 75762 |
Arm-DOTA-B72.3 |
77 |
h |
2024-12-19 |
| 75763 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
93 |
zyl |
2024-12-19 |
| 75764 |
(Lys(DOTA)4)BVD15 DOTA偶联神经肽Y(NPY)类似物 |
126 |
h |
2024-12-19 |
| 75765 |
1801838-28-7，Mc-vc-PAB-SN38，化合物MC-VC-PAB-SN38 |
87 |
kx |
2024-12-19 |
| 75766 |
DOTA-PPI 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-官能化的聚(丙烯亚胺)(PPI)糖树枝状分子 |
89 |
h |
2024-12-19 |
| 75767 |
CAS: 863971-17-9，MC-Val-Cit-PAB-MMAF |
110 |
WYQ |
2024-12-19 |
| 75768 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
124 |
zyl |
2024-12-19 |
| 75769 |
DBCO-PEG4-vc-PAB-MMAE， ADC试剂 |
112 |
kx |
2024-12-19 |
| 75770 |
1884578-00-0，Boc-PEG4-Val-Ala-PAB-PNP，ADC定制 |
114 |
wyh |
2024-12-19 |
| 75771 |
DOTA-Peg-Cpa-c[DCys-Aph(Cbm)-DTrp-Lys-Thr-Cys]-2Nal-NH2 |
77 |
h |
2024-12-19 |
| 75772 |
DOTA-2.5D DOTA-胱氨酸结肽(knottins)2.5D和2.5F |
94 |
h |
2024-12-19 |
| 75773 |
二苯并环辛炔-四聚乙二醇-VAL-ALA-PAB，ADC定制 |
114 |
wyh |
2024-12-19 |
| 75774 |
Hz220(DOTA-Lys(IR dye 650)-PEa(4)-[D-Phe(6)DOTA偶联的GRPr拮抗剂 |
91 |
h |
2024-12-19 |
| 75775 |
Azido-PEG4-MMAE，抗体药物偶联物（ADCs） |
123 |
WYQ |
2024-12-19 |
| 75776 |
1626359-62-3，SPDB-DM4， ADC试剂 |
81 |
kx |
2024-12-19 |
| 75777 |
Acid-PEG4-Val-Cit-PAB-MMAE，包含PEG链和MMAE等部分 |
87 |
WYQ |
2024-12-19 |
| 75778 |
cas:159857-70-2，MC-Val-Cit-Doxorubicin，ADC定制 |
110 |
wyh |
2024-12-19 |
| 75779 |
DOTA-(D)Phe(1)-Tyr(3) |
82 |
h |
2024-12-19 |
| 75780 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
123 |
zyl |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询